Sign In
Buy AVDL
$21.64
+0 (+0%)
At Close: May 08, 2026
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
08:00am, Monday, 01'st Apr 2024
DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that me
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
08:00am, Tuesday, 05'th Mar 2024
DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that me
Avadel Pharmaceuticals Issues Statement On Patent Litigation
03:37pm, Monday, 04'th Mar 2024
DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the Distr
Avadel Pharmaceuticals plc (AVDL) Q4 2023 Earnings Call Transcript
10:43am, Monday, 04'th Mar 2024
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2023 Earnings Conference Call March 4, 2024 7:30 AM ET Company Participants Austin Murtagh - Stern IR Gregory Divis - CEO Richard Kim - Chief Commercial Of
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
06:30am, Monday, 04'th Mar 2024
-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ -- -- As of January 31 st , greater than 2,200 patients enrolled in RYZUP TM and mo
Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
02:56am, Sunday, 28'th Jan 2024
Avadel Pharmaceuticals has made good progress with the launch of Lumryz, enrolling 1,900 patients and generating $19 million in Q4 net sales. Legal risks from competitor Jazz Pharmaceuticals remain a
Here's Why You Should Invest in Avadel (AVDL) Stock Now
11:36am, Thursday, 18'th Jan 2024
Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?
01:32pm, Monday, 15'th Jan 2024
Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
How Much Upside is Left in Avadel (AVDL)? Wall Street Analysts Think 37.36%
11:17am, Monday, 15'th Jan 2024
The consensus price target hints at a 37.4% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Why Avadel Pharmaceuticals (AVDL) Stock Might be a Great Pick
09:47am, Friday, 12'th Jan 2024
Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Avadel May Continue To Outperform With Positive Launch Momentum
11:31am, Thursday, 11'th Jan 2024
Avadel Pharma's launch of its product LUMRYZ is expected to drive the company's stock performance. LUMRYZ appears to have momentum and is differentiated from current narcolepsy treatments. The potenti
Avadel Pharmaceuticals PLC (AVDL) Q3 2023 Earnings Call Transcript
01:48pm, Wednesday, 08'th Nov 2023
Avadel Pharmaceuticals PLC (NASDAQ:AVDL ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Austin Murtagh - Stern Investor Relations Gregory Divis - CEO & Director Ric
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
07:00am, Wednesday, 08'th Nov 2023
-- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch -- -- Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUP TM and more than 400 pati
– 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option –
Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit
08:00am, Thursday, 05'th Oct 2023
DUBLIN, Ireland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem
